A cell-based approach to characterize antimicrobial compounds through kinetic dose response

Area of Science:

• Microbiology
• Pharmacology
• Drug Discovery

Background:

• Antibiotic resistance is a growing global health threat, necessitating new drug discovery platforms.
• Current screening methods may not fully capture the complex interactions of antimicrobial compounds.
• There is a need for efficient and informative methods to characterize novel small molecules for antibiotic development.

Purpose of the Study:

• To investigate the utility of cell-based kinetic dose response curves for characterizing antimicrobial small molecules.
• To demonstrate how kinetic profiles can classify antibiotics by their mechanism of action.
• To highlight the potential of kinetic dose response for predicting off-target effects and identifying unstable compounds.

Main Methods:

• Kinetically monitoring bacterial growth at sub-inhibitory concentrations of various antimicrobial small molecules.
• Generating unique dose response profiles based on bacterial growth characteristics.
• Employing clustering algorithms to group profiles and correlate them with known antibiotic mechanisms.
• Analyzing changes in growth kinetics to infer mechanistic action and predict potential off-target effects.

Main Results:

• Kinetic dose response profiles effectively distinguished between antibiotics with different mechanisms of action.
• Changes in bacterial growth kinetics provided insights into the mechanistic action of novel compounds.
• The method identified potential off-target effects through structure-activity relationship analysis.
• Kinetic dose response facilitated the early detection of unstable drug candidates.

Conclusions:

• Cell-based kinetic dose response curves offer a rapid and cost-effective approach for small molecule characterization in antibiotic discovery.
• This kinetic method enhances hit selection and lead development by providing critical mechanistic and stability information.
• The approach has the potential to accelerate the development pipeline for new antimicrobial agents.